Trial document

This study has been imported from without additional data checks.
drksid header


Trial Description

start of 1:1-Block title


Wave IV Study: Phase II Randomized Sham Controlled Study of Renal Denervation for Subjects With Uncontrolled Hypertension

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym


end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial


end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

To demonstrate that non-invasive renal denervation is safe and shows a net difference in
blood pressure reduction when compared to sham in subjects with uncontrolled hypertension.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

This study is a sham controlled, double blind study of subjects with uncontrolled
hypertension consisting of two arms, sham and therapy. Bilateral renal denervation will be
performed non-invasively using the Kona Medical Surround Sound System which delivers focused
ultrasound therapy to ablate the nerves surrounding the renal artery utilizing real time
ultrasound for targeting and tracking.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00005865
  •   2014/09/10
  •   2014/01/06
  •   no
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   NCT02029885  (
  •   KM14-001  (Kona Medical Inc.)
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Hypertension
  •   I10-I15 -  Hypertensive diseases
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Device: Investigational Therapy (Surround Sound)
  •   Device: Sham Control
end of 1:N-Block interventions
start of 1:1-Block design


  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Blinded
  •   patient/subject, investigator/therapist
  •   Placebo
  •   Treatment
  •   Parallel
  •   N/A
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- Safety at 6 weeks follow-up; time frame: 6 weeks; Safety will be assessed by incidence of Major Adverse Events (MAE), defined as a composite of the following events at 6-weeks follow-up.
All cause mortality;
End-stage Renal Disease defined as eGFR < 15 ml/min or need for renal replacement therapy
Hospitalization for hypertensive crisis not related to confirmed non-adherence with medications as assessed by toxicological and other medical analyses and testing.
- New renal artery stenosis > 70% confirmed by angiography within 6 months of randomization
- Change in OBP; time frame: 6 months; Change in Office Systolic Blood Pressure (OBP) as measured from screening visit one to the 6 month post randomization follow-up visit.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- Change in ABPM; time frame: 6 months; Change in average 24-hour ambulatory blood pressure from screening to the 6 month follow-up visit

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Australia
  •   Austria
  •   Colombia
  •   Czech Republic
  •   Germany
  •   New Zealand
  •   Poland
  •   United Kingdom
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

end of 1:n-Block recruitment locations
start of 1:1-Block recruitment


  •   [---]*
  •   2014/08/31
  •   132
  •   Multicenter trial
  •   International
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   90   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

1. Subject is at least 18 years of age and no more than 90 years of age

2. Average SBP ≥ 160 mmHg

3. 24 hour average ABPM daytime SBP ≥ 135 mmHg.

4. No medication changes for a minimum of 1 months prior to screening.

5. At minimum, subject must be on at least three antihypertensive medications, with one
being a diuretic, and each must meet one or more of the following full dose criteria:

1. Highest labeled dose according to medication's labeling;

2. Highest usual dose per clinical guidelines JNC-7;

3. Highest tolerated dose; and/or

4. Highest appropriate dose for the subject per the PI's clinical judgment.

6. Subject has two functioning kidneys.

7. Subject has an eGFR value of ≥ 30 ml/min/1.73 m² (MDRD formula).

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

1. Subject has any secondary cause of hypertension

2. Subject has evidence of clinically significant renal artery stenosis as determined by
flow rate, velocity and Doppler analysis on ultrasound

3. Subject has kidney stones that are of a size and location that are determined at
discretion of the investigator to potentially interfere with treatment

4. Subject has a history of intra-abdominal surgery within the past six months

5. Subject has heterogeneities in the kidney such as large cysts or tumors that are
determined at discretion of the investigator to potentially interfere with treatment.

6. Stenotic valvular heart disease for which BP reduction would be hazardous as
determined by referring physician.

7. MI, unstable angina, or CVA in the prior 6 months.

8. Known severe primary pulmonary HTN

9. Subject has a history of myocardial infarction, unstable angina pectoris, or
cerebrovascular accident within the last six months.

10. Subject has hemodynamically significant valvular heart disease.

11. Subject has BMI over 40 km/m^2

12. Subject has a target treatment depth over 13 cm.

13. Subject has anatomy that precludes treatment with the Kona Medical Surround Sound

14. Subject is pregnant, nursing, or intends to become pregnant during the trial period.

15. Subject is currently enrolled in other potentially confounding research.

16. Subject has any condition that, at the discretion of the investigator, would preclude
participation in the trial.

17. Subject is unable, or unwilling, to comply with the protocol-required follow-up

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses


  • start of 1:1-Block address primary-sponsor
    • Kona Medical Inc.
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • University Hospital of University of Erlangen-Nuremberg
    • Roland Schmieder, MD 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Omar Dawood 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state


  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
The parameters in and DRKS are not identical. Therefore the data import from required adjustments. For full details please see the DRKS FAQs .
  •   2
  •   2014/11/27
* This entry means the parameter is not applicable or has not been set.